NCT06254313 The Role of Cxcr4Hi neutrOPhils in InflueNza
| NCT ID | NCT06254313 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Bordeaux |
| Condition | Influenza |
| Study Type | OBSERVATIONAL |
| Enrollment | 90 participants |
| Start Date | 2024-12 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 90 participants in total. It began in 2024-12 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Influenza is still responsible for more than 650,000 deaths per year worldwide and no major improvements in patients' care has been made despite 50 years of research. Especially, there is no therapeutic strategy targeting the dysregulated host response. CXCR4-expressing neutrophils seem to be involved in the rupture of host resistance. The aim of this study is thus to compare the percentage of blood CXCR4-expressing neutrophils between influenza survivors and non-survivors.
Eligibility Criteria
Inclusion Criteria: * Patient aged 18 yo or above. * Acute respiratory distress syndrome as defined by the Berlin classification. * Invasive mechanical ventilation for less than 24 hours. * Cause of ARDS: * Influenza infection proven by polymerase chain reaction OR * Bacterial infection (tracheal aspirate with more than 105 CFU/mL and BAL with more than 104 CFU/mL. * Pancreatitis according to the 2013 Working Group IAP/APA Acute Pancreatitis Guidelines. * Peritonitis according to the 2018 SFAR guidelines. * Health insurance. * Written informed consent from legal relative or representative. Exclusion Criteria: * Neutropenia (\< 500/mm3) * Neutrophils qualitative defect. * Patient included in an interventional research assessing an immunomodulatory or antiviral drug. * Acquired ImmunoDeficiency Syndrome. * Contraindication to BAL: * Severe bronshospasm. * Out-of-control shock. * Intracranial high pressure. * Refractory hypoxemia (PaO2/FiO2 \< 60 mmHg). * Legal restriction: prisoners, pregnancy, legal protection.
Contact & Investigator
Edouard LHOMME, Dr
STUDY CHAIR
Unité de Soutien Méthodologique à la Recherche clinique et épidémiologique du CHU de Bordeaux
Frequently Asked Questions
Who can join the NCT06254313 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Influenza. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06254313 currently recruiting?
Yes, NCT06254313 is actively recruiting participants. Contact the research team at renaud.prevel@u-bordeaux.fr for enrollment information.
Where is the NCT06254313 trial being conducted?
This trial is being conducted at Bordeaux, France, Pessac, France.
Who is sponsoring the NCT06254313 clinical trial?
NCT06254313 is sponsored by University Hospital, Bordeaux. The principal investigator is Edouard LHOMME, Dr at Unité de Soutien Méthodologique à la Recherche clinique et épidémiologique du CHU de Bordeaux. The trial plans to enroll 90 participants.